Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Genitourinary Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting Aug 19, 2026

Show notes

Featuring perspectives from Dr Rahul Aggarwal, Dr Matthew D Galsky and Dr Tian Zhang, including the following topics:

Introduction: Welcome GU Oncology Fellows! (0:00)
Prostate Cancer — Dr Aggarwal (12:48)
Urothelial Bladder Cancer — Dr Galsky (45:01)
Renal Cell Carcinoma — Dr Zhang (1:10:52)

CME information and select publications

For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress Aug 18, 2026

Show notes

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

· Introduction (0:00)

· Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)

· Practical Considerations with Oral SERDs (15:42)

· Potential Role of Combination Approaches with Oral SERDs (26:31)

· Gastrointestinal Adverse Events Documented with Oral SERDs (38:17)

· Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51)

· Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53)

· Emerging Utility of Adjuvant Oral SERDs (1:10:16)

· Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 6 Aug 18, 2026

Show notes

Featuring perspectives from Prof Yohann Loriot, including the following topics:

Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00)
Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences hyperglycemia and cancer progression, then receives erdafitinib and experiences elevated phosphase, Grade 2 diarrhea and stomatitis and eventual disease progression — Jacqueline T Brown, MD (7:00)
Case: A man in his late 80s with mUBC receives first-line EV/pembrolizumab and develops pneumonitis — Fern Anari, MD (17:40)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 5 Aug 17, 2026

Show notes

Featuring perspectives from Prof Yohann Loriot, including the following topics:

Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00)
Case: A man in his early 90s with excellent PS and locally advanced UBC receives EV and pembrolizumab as palliative treatment, develops neuropathy, discontinues the EV and continues pembrolizumab with no toxicity — Catherine Fahey, MD, PhD (12:01)
Case: A woman in her late 50s with metastatic UBC receives EV with pembrolizumab on a clinical trial and experiences a response but develops diarrhea and pruritus — Fern Anari, MD (21:43)

CME information and select publications

Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances Aug 17, 2026

Show notes

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:

Introduction (00:00)
Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)
Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)
Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)
ASCO and EHA 2026 (46:37)

CME information and select publications

Multiple Myeloma | Robert Z Orlowski, MD, PhD Aug 17, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma — Robert Z Orlowski, MD, PhD

CME information and select publications

Multiple Myeloma | Amrita Krishnan, MD Aug 17, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor T‑Cell Therapy, Bispecific Antibodies and Antibody‑Drug Conjugates — Amrita Krishnan, MD

CME information and select publications

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Aug 15, 2026

Show notes

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

Case: A woman in her late 60s with T3N0 upper tract urothelial carcinoma that was resected has no evidence of disease on imaging, receives negative circulating tumor DNA results and elects observation instead of adjuvant treatment (0:00)
Case: A man in his late 70s with PD-L1-negative high-grade muscle-invasive bladder cancer who is ineligible for cisplatin because of poor renal function undergoes cystectomy (10:12)

CME information and select publications

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Aug 14, 2026

Show notes

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

Case: A healthy man in his early 70s who received several different lines of therapy for non-muscle-invasive bladder cancer (NMIBC), wants to avoid radical cystectomy and does not want pembrolizumab (0:00)
Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (11:20)

CME information and select publications

Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies Aug 13, 2026

Show notes

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:

Introduction (0:00)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)
Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)
CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)
Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24)
Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected